WordPress database error: [Table 'ajvhvamy_kesho.kesho_wfconfig' doesn't exist]
SELECT COUNT(*) FROM kesho_wfconfig WHERE name = 'scan_exclude'

WordPress database error: [Table 'ajvhvamy_kesho.kesho_wfconfig' doesn't exist]
SHOW FULL COLUMNS FROM `kesho_wfconfig`

BEGIN:VCALENDAR VERSION:2.0 PRODID:-//KESHO - ECPv6.17.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:KESHO X-ORIGINAL-URL:https://kesho-kenya.org X-WR-CALDESC:Events for KESHO REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Africa/Nairobi BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0300 TZNAME:EAT DTSTART:20250101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260416T190000 DTEND;TZID=Africa/Nairobi:20260416T203000 DTSTAMP:20260526T193940Z CREATED:20260526T192507Z LAST-MODIFIED:20260526T193940Z UID:41705-1776366000-1776371400@kesho-kenya.org SUMMARY:Bridging Surgery and Oncology in Head & Neck Cancer DESCRIPTION:Moderator: Dr. Ahmed Komen\nSpeakers: Dr. Anthony Kenyanya\, Dr. Anthony Ndiritu\nDate: 16 April 2026\n\nThis session explored the management of head and neck cancer with particular attention to how surgical decisions and oncology pathways must align from the outset. Through oral cavity cancer as a key focus\, the session examined resectability\, margins\, nodal management\, reconstruction\, adjuvant therapy and functional outcomes. \nA central theme was that treatment planning must go beyond tumour removal. Dr. Anthony Kenyanya highlighted the importance of staging\, imaging\, pathology\, dental and nutritional assessment\, surgical access\, margin planning and neck node evaluation. In oral cavity cancers\, surgical success depends not only on clear oncologic resection\, but also on the ability to reconstruct defects and preserve speech\, swallowing\, appearance and quality of life. \nThe discussion also emphasised the challenge of late presentation and complex anatomy. Selective neck dissection\, sentinel node considerations\, access procedures such as mandibulotomy\, and the reconstructive ladder were framed as tools for balancing disease control with morbidity. The role of the pathologist and margin assessment was highlighted as central to determining risk and guiding further treatment. \nDr. Anthony Ndiritu built on this by outlining how radiotherapy and chemoradiation fit into early\, locally advanced\, post-operative\, recurrent and metastatic diseases. Early-stage disease may often be treated with a single modality\, while locally advanced disease requires careful integration of surgery\, radiotherapy and chemotherapy. \nPositive margins and extranodal extension were discussed as major indications for post-operative chemoradiation\, with timely initiation of treatment after surgery being important. The session also addressed treatment technique\, patient fitness\, nutrition\, supportive care and the need to tailor recommendations to the services and expertise available. \nAcross the session\, a consistent message emerged: head and neck cancer care is as much about function\, coordination and follow-through as it is about disease control. \nKey Takeaways\n\nHead and neck cancer decisions must integrate tumour stage\, resectability\, patient fitness and functional outcomes.\nMargin planning\, pathology reporting and neck node assessment directly shape adjuvant treatment decisions.\nSurgery requires strong reconstruction and rehabilitation planning to preserve speech\, swallowing and appearance.\nLocally advanced disease often needs combined-modality treatment through an MDT approach.\nPositive margins and extranodal extension are key triggers for post-operative chemoradiation.\nSupportive care\, nutrition and patient navigation are essential to treatment completion. URL:https://kesho-kenya.org/event/bridging-surgery-and-oncology-in-head-neck-cancer/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/Bridging-Surgery-and-Oncology-in-Head-Neck-Cancer-e1779824360609.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260430T190000 DTEND;TZID=Africa/Nairobi:20260430T203000 DTSTAMP:20260526T194041Z CREATED:20260526T192028Z LAST-MODIFIED:20260526T194041Z UID:41701-1777575600-1777581000@kesho-kenya.org SUMMARY:Multidisciplinary Management of Testicular Cancer DESCRIPTION:Moderator: Dr. Muigai Mararo\nSpeakers: Dr. Dedan Opondo\, Dr. Joseph Abuodha\, Dr. George Ogweno\nDate: 30 April 2026\n\nThis session marked Testicular Cancer Awareness Month with a multidisciplinary discussion on diagnosis\, primary management\, advanced disease\, relapse and fertility preservation. \nA central theme was that testicular cancer is highly curable when investigated and managed promptly\, but cure depends on disciplined staging and risk stratification. Dr. Dedan Opondo outlined the importance of early clinical recognition\, scrotal ultrasound\, serum tumour markers\, cross-sectional imaging and radical inguinal orchiectomy. The session reinforced that suspected testicular cancer should not be delayed\, particularly because some germ cell tumours can progress rapidly. \nStaging was presented as a practical foundation for management. Tumour markers such as AFP\, beta-HCG and LDH\, together with nodal imaging and histology\, help distinguish seminomatous from non-seminomatous disease and guide decisions on surveillance\, chemotherapy\, radiotherapy and retroperitoneal lymph node dissection. The discussion also highlighted the technical and fertility-related implications of retroperitoneal surgery in young men. \nDr. Joseph Abuodha reviewed advanced and relapsed disease\, emphasising that treatment remains strongly anchored in surgery\, cisplatin-based chemotherapy\, radiotherapy and surveillance rather than newer targeted or immunotherapy approaches. Across stages\, the emphasis was on matching intensity to risk—avoiding both overtreatment and undertreatment—while recognising that even metastatic disease can remain curable with the right treatment strategy. \nDr. George Ogweno brought fertility preservation into the core of cancer care. He underscored the need for early oncofertility counselling\, sperm banking where possible before treatment\, and stronger collaboration between oncology\, urology\, fertility specialists\, laboratories and counsellors. The discussion also reflected Kenya’s service realities\, including limited fertility centres and the need for clearer pathways\, consent and long-term storage planning. \nAcross the session\, a consistent message emerged: testicular cancer care must protect both survival and survivorship. \nKey Takeaways\n\nEarly recognition\, tumour markers\, imaging and radical inguinal orchiectomy are central to initial management.\nRisk stratification using histology\, TNM stage and post-operative markers guides treatment intensity.\nSeminoma and non-seminoma pathways differ and should not be managed interchangeably.\nCisplatin-based chemotherapy remains central in advanced and relapsed disease.\nSurveillance is appropriate only when reliable follow-up is possible.\nFertility counselling and sperm preservation should be discussed as early as possible. URL:https://kesho-kenya.org/event/multidisciplinary-management-of-testicular-cancer/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/Multidisciplinary-Management-of-Testicular-Cancer.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260507T190000 DTEND;TZID=Africa/Nairobi:20260507T203000 DTSTAMP:20260525T210319Z CREATED:20260525T193909Z LAST-MODIFIED:20260525T210319Z UID:41667-1778180400-1778185800@kesho-kenya.org SUMMARY:From Data to Discovery: Leveraging Registries and Clinical Insights to Advance Research DESCRIPTION:Moderator: Rebecca Mwakichako\nDate: 7th May 2026\nSpeakers: Dr. Thomas Chatzikonstantinou\, Ms. Anne Korir \nThis session examined how routine clinical data can be transformed into meaningful research evidence\, with a focus on real-world data\, clinical registries and everyday documentation as a foundation for local oncology research. \nA central theme was the value of real-world evidence as a complement to randomized controlled trials. Dr. Thomas Chatzikonstantinou outlined how registries and clinical databases can help answer questions on treatment patterns\, long-term outcomes\, low-prevalence biomarkers\, health economics and implementation across diverse settings. He emphasized that good research begins with realistic questions\, clear endpoints and attention to data quality. \nMs. Anne Korir grounded the discussion in the Kenyan cancer registry experience\, highlighting how paper files\, unstructured notes\, missing staging information\, weak follow-up documentation and inconsistent residence or risk-factor data can limit the research value of clinical records. She underscored the need for standardization\, digitization\, regular data cleaning and ethical governance. \nAcross the session\, a consistent message emerged: every clinical encounter can contribute to discovery when documentation is structured\, complete and designed with future learning in mind. \n  Key Takeaways \n\nReal-world data complements clinical trials by showing how care is delivered in routine practice.\nRoutine clinical notes can generate locally relevant oncology research questions.\nStandardized documentation is essential for usable research and registry data.\nCancer registries remain critical for surveillance\, policy and outcome tracking.\nCollaboration between clinicians\, registries and research institutions can strengthen local evidence generation.\n\n  \n  URL:https://kesho-kenya.org/event/from-data-to-discovery-leveraging-registries-and-clinical-insights-to-advance-research/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/From-Data-to-Discovery.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260514T190000 DTEND;TZID=Africa/Nairobi:20260514T203000 DTSTAMP:20260525T210044Z CREATED:20260525T203403Z LAST-MODIFIED:20260525T210044Z UID:41670-1778785200-1778790600@kesho-kenya.org SUMMARY:Melanoma Care in Practice: Integrating Dermatology\, Surgery & Oncology DESCRIPTION:Moderator: Dr Stephen Chege\nDate: 14th May 2026\nSPEAKERS: Dr. Hannah Wanyika\, Dr. Esther Gathura\, Dr. Angela McLigeyo \nThis session examined melanoma care across the clinical pathway\, from recognition of suspicious skin lesions to biopsy\, excision\, reconstruction\, staging and systemic treatment. \nA central theme was the importance of early suspicion and timely tissue diagnosis. Dr. Hannah Wanyika highlighted practical indications for biopsy\, including new or changing pigmented lesions\, non-healing ulcers\, evolving moles and lesions that differ from surrounding skin. The discussion reinforced the use of the ABCDE approach and the “ugly duckling” sign\, while emphasizing that changing lesions on the palms\, soles\, nails and scalp should not be dismissed. \nDr. Esther Gathura explored the surgical and reconstructive dimensions of melanoma care\, particularly the realities of acral melanoma\, which is common in African populations and often presents late. She emphasized the role of mapping biopsies\, Breslow thickness\, ulceration\, nodal assessment and multidisciplinary planning in balancing oncologic safety with function\, especially for weight-bearing areas of the foot. \nDr. Angela McLigeyo outlined the major advances in systemic therapy for advanced melanoma\, including immune checkpoint inhibitors\, targeted therapy and emerging treatment strategies. While immunotherapy has transformed outcomes globally\, the session also acknowledged access\, affordability and the urgent need for local data to guide treatment decisions in Kenya and the region. \nAcross the session\, a consistent message emerged: optimal melanoma care depends on early recognition\, accurate biopsy\, careful staging\, function-preserving surgery and realistic access to effective systemic therapy. \nKey Takeaways \n\nChanging pigmented lesions\, non-healing ulcers and suspicious nail or acral lesions require timely biopsy.\nThe ABCDE rule and “ugly duckling” sign remain useful tools in clinical assessment.\nAcral melanoma presents distinct diagnostic and surgical challenges in African settings.\nSurgical management must balance clear margins\, staging and functional reconstruction.\nImmunotherapy and targeted treatment have changed advanced melanoma care\, but access and local evidence remain key challenges. URL:https://kesho-kenya.org/event/melanoma-care-in-practice-integrating-dermatology-surgery-oncology/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/Melanoma-Care.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260521T190000 DTEND;TZID=Africa/Nairobi:20260521T203000 DTSTAMP:20260526T194356Z CREATED:20260525T210458Z LAST-MODIFIED:20260526T194356Z UID:41677-1779390000-1779395400@kesho-kenya.org SUMMARY:Bladder Cancer Care DESCRIPTION:SPEAKERS: Dr. Patrick Mbuthia\, Dr. Helena Musau\, Dr Mohammed Ezzi\nDate: 21st May 2026\nModerator: Dr. Sitna Mwanzi \nThis session examined bladder cancer through a multidisciplinary lens\, bringing together surgical\, radiotherapeutic and systemic treatment perspectives across the continuum of care. \nA central theme was the need for accurate staging and risk-adapted management. Dr. Patrick Mbuthia discussed the role of transurethral resection of bladder tumour (TURBT) in diagnosis\, staging and treatment\, particularly for non-muscle invasive disease. The importance of complete resection\, adequate detrusor muscle in the specimen\, careful imaging and attention to complications was emphasized as central to subsequent treatment decisions. \nDr. Helena Musau highlighted the evolving role of radiotherapy in bladder preservation\, especially through tri-modality therapy combining maximal TURBT\, concurrent chemoradiation and structured response assessment. The discussion also addressed patient selection\, surveillance\, salvage options\, palliative radiotherapy for symptoms\, and the value of newer radiotherapy techniques in reducing toxicity while preserving quality of life. \nDr. Mohammed Ezzi reviewed systemic treatment across non-muscle invasive\, muscle invasive and metastatic bladder cancer. He outlined the role of intravesical therapy\, BCG\, cisplatin eligibility\, immunotherapy\, maintenance strategies and emerging options such as antibody-drug conjugates and targeted agents\, while noting that cost and availability continue to shape real-world treatment in Kenya. \nAcross the session\, a consistent message emerged: improving bladder cancer outcomes requires timely diagnosis\, high-quality TURBT\, multidisciplinary decision-making and treatment pathways that reflect both evidence and local access reality. \nKey Takeaways \n\nBladder cancer management depends on accurate staging and distinction between non-muscle invasive and muscle invasive disease.\nHigh-quality TURBT with adequate muscle sampling is central to diagnosis and treatment planning.\nTrimodality therapy offers bladder preservation for carefully selected patients.\nSystemic therapy is rapidly evolving with immunotherapy\, maintenance approaches and antibody-drug conjugates.\nLocal data are needed to address African patterns of disease\, including schistosomiasis-associated squamous cell carcinoma.\n\n  URL:https://kesho-kenya.org/event/bladder-cancer-care/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/Bladder-Cancer-Care-e1779824625799.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260528T190000 DTEND;TZID=Africa/Nairobi:20260528T203000 DTSTAMP:20260529T182745Z CREATED:20260525T190142Z LAST-MODIFIED:20260529T182745Z UID:41658-1779994800-1780000200@kesho-kenya.org SUMMARY:The Brain Tumour Journey DESCRIPTION:Speakers: Dr. Michael Magoha; Dr. Sarah Muma; Dr. Parmenas Minda Okemwa\nModerator: Mr. David L. Oluoch-Olunya \nThe Brain Tumour Journey brought together neurosurgery\, paediatric haemato-oncology and neuropathology perspectives to examine how multidisciplinary collaboration can improve care for patients with brain tumours. The session positioned brain tumour management as a continuum\, from first symptoms and referral to surgery\, pathology\, oncology treatment\, rehabilitation\, follow-up and family support. \nDr. Michael Magoha opened the session by reframing the brain tumour journey around the patient experience. He noted that brain tumours often carry fear and uncertainty\, yet they are not a single diagnosis or a uniform prognosis. With more than 150 tumour types and subtypes\, the patient’s pathway can vary widely. His presentation highlighted the role of patient navigation in helping individuals move through imaging\, surgery\, pathology\, endocrine review\, oncology care and long-term follow-up without being lost in fragmented systems. \nDr. Sarah Muma focused on the multidisciplinary management of childhood brain tumours in Kenya. She highlighted that brain and CNS tumours appear under-recognised in local and African childhood cancer data\, suggesting delays in diagnosis and referral. Children may present with persistent headaches\, vomiting\, visual changes\, seizures\, gait or coordination problems\, abnormal head growth\, behavioral changes or endocrine-related symptoms. The discussion emphasized the need for a higher index of suspicion\, especially when symptoms are progressive\, recurrent or not responding as expected. \nThe session also examined Kenyan system-level challenges\, including limited access to timely imaging\, prolonged pathways between surgery and radiotherapy\, scarcity of formal paediatric neuro-oncology programs and treatment abandonment. Dr. Muma described the value of neuro-oncology multidisciplinary clinics\, where patients and families can receive coordinated input from neurosurgery\, oncology\, radiology\, pathology\, rehabilitation\, counselling and navigation teams within a more structured care pathway. \nDr. Parmenas Minda Okemwa closed the presentations by discussing the principles and diagnostic challenges of brain tumour pathology. He emphasized that pathology remains the gold standard for diagnosis\, but modern brain tumour care increasingly depends on integrated reporting that combines clinical context\, radiology\, histology\, immunohistochemistry and molecular testing. His presentation underscored the need for adequate tissue sampling\, stronger neuropathology capacity\, expanded diagnostic panels\, molecular testing access and regular multidisciplinary tumour board discussions. \nAcross the session\, the message was clear: improving brain tumour outcomes requires coordinated systems\, not isolated excellence. Timely diagnosis\, accurate pathology\, surgical expertise\, oncology planning\, patient navigation\, rehabilitation and survivorship support must work together if patients are to receive care that is clinically sound\, humane and sustainable. \nKey Takeaways\n\nBrain tumour care is a journey\, not a single event. Patients often require coordinated input across imaging\, surgery\, pathology\, oncology treatment\, rehabilitation and follow-up.\nPatient navigation can reduce fragmentation. Navigators help patients and families move through complex health systems and reduce the risk of missed appointments\, delayed reviews or incomplete follow-up.\nChildren may present with subtle or progressive symptoms. Persistent headaches\, seizures\, visual changes\, gait problems\, behavioural changes or endocrine symptoms should prompt a high index of suspicion.\nMultidisciplinary clinics can shorten delays. Same-day or coordinated review by several specialists can improve treatment planning and reduce the burden on families.\nAccurate diagnosis depends on integrated pathology. Histology remains central\, but immunohistochemistry and molecular testing increasingly guide classification\, prognosis and treatment options.\nKenya’s neuro-oncology systems are advancing but need strengthening. Referral pathways\, registries\, specialist training\, diagnostic capacity\, molecular testing access and survivorship systems remain key priorities. URL:https://kesho-kenya.org/event/advancing-care-through-multidisciplinary-collaboration/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/WhatsApp-Image-2026-05-28-at-3.56.29-PM-1-e1780079236823.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260611T190000 DTEND;TZID=Africa/Nairobi:20260611T203000 DTSTAMP:20260629T093247Z CREATED:20260609T080719Z LAST-MODIFIED:20260629T093247Z UID:41725-1781204400-1781209800@kesho-kenya.org SUMMARY:Strengthening Haemato-Oncology Care DESCRIPTION:STRENGTHENING HAEMATO-ONCOLOGY CARE THROUGH PALLIATIVE CARE AND RESEARCH EXCELLENCE \n\nModerator: Prof. John Weru\nSpeaker: Prof. Sayed Karar\nDate: 11 June 2026\n\nThis session examined palliative care as a critical component of quality and comprehensive haemato-oncology care. The discussion challenged the misconception that palliative care belongs only at the end of life and instead presented it as an added layer of support that can be introduced early\, alongside active treatment. \nA central theme was the distinction between palliative care and hospice. Prof. Sayed Karar emphasized that palliative care can support patients and families at any stage of serious illness\, including during chemotherapy\, radiotherapy or other disease directed treatment. Hospice care\, by contrast\, is generally associated with advanced disease when curative options are no longer appropriate. The discussion framed palliative care as a holistic service that addresses pain\, symptoms\, psychological distress\, spiritual concerns\, social needs and family burden. \nThe session also situated palliative care within the African and Kenyan context. Prof. Karar highlighted the large unmet need for palliative care across the continent\, the uneven availability of services\, limited access to opioids and the continued underuse of affordable medicines such as morphine. Local studies were used to show how research can change practice\, including ICU trigger models that help identify patients who should receive timely palliative care review. \nThrough case scenarios\, the discussion explored difficult conversations\, symptom control\, prognostication\, end of life feeding\, dialysis decisions\, family conflict and the role of faith and hope in care decisions. Practical tools such as the SPIKES framework were discussed as a way to support clear\, compassionate communication. The session also reinforced the importance of identifying the appropriate decision maker\, using plain language and allowing families time to process serious news. \nAcross the session\, a consistent message emerged: palliative care is not about withdrawing care. It is about strengthening care\, relieving suffering\, supporting decision making and helping patients and families navigate serious illness with dignity. \nKey Takeaways \n\nPalliative care should be introduced early and can run alongside active haemato-oncology treatment.\nHospice and palliative care are related but not the same; palliative care is appropriate at any stage of serious illness.\nPain control requires careful assessment\, stepwise treatment\, safe opioid use and attention to side effects such as constipation.\nDifficult conversations need preparation\, privacy\, clear language\, empathy and structured follow up.\nLocal palliative care research can influence practice\, including the use of triggers to identify patients who need timely review.\nEvery clinician should have basic palliative care skills\, especially in settings where specialist services are limited. URL:https://kesho-kenya.org/event/strengthening-haemato-oncology-care/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/06/WhatsApp-Image-2026-06-09-at-6.28.14-AM-e1780992584937.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260618T190000 DTEND;TZID=Africa/Nairobi:20260618T203000 DTSTAMP:20260617T133652Z CREATED:20260617T080505Z LAST-MODIFIED:20260617T133652Z UID:41730-1781809200-1781814600@kesho-kenya.org SUMMARY:Nutrition into Oncology DESCRIPTION:Integrating Nutrition into Oncology Practice \nFueling Better Outcomes \n📅 Date: 18th June 2026\n🕖 Time: 7 PM – 8:30 PM EAT\n🏅 CPD Accredited \nMODERATOR\nKennedy Okinda\nOncology Nutrition Specialist\, Mwai Kibaki Referral Hospital \nSPEAKER\nNjoki Karanja\nOncology Nutrition Specialist\nNutrition in Cancer Care: From Treatment to Recovery \nSPEAKER\nDr. Andrew Odhiambo\nMedical Oncologist\, The Nairobi Hospital; Thematic Head & Program Director\, Medical Oncology\, UON\nThe Clinical Impact of Nutrition on Cancer Outcomes URL:https://kesho-kenya.org/event/nutrition-into-oncology/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/06/WhatsApp-Image-2026-06-17-at-2.19.27-PM-1-e1781703392442.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260625T193000 DTEND;TZID=Africa/Nairobi:20260625T203000 DTSTAMP:20260629T093106Z CREATED:20260624T084816Z LAST-MODIFIED:20260629T093106Z UID:41736-1782415800-1782419400@kesho-kenya.org SUMMARY:Sickle Cell Disease DESCRIPTION:SICKLE CELL DISEASE: FROM NEWBORN DETECTION TO LONG-TERM OUTCOMES \n\nModerator: Dr. Fatmah Abdallah\nSpeakers: Dr. Bernard Awuonda and Dr. Sophie Uyoga\n\nThis session examined sickle cell disease through the full patient pathway\, from newborn detection and early diagnosis to long-term care\, survival and health-system readiness. \nDr. Bernard Awuonda opened the session by situating sickle cell disease as an inherited haemoglobin disorder and emphasising the importance of public education in reducing stigma. The discussion highlighted that sickle cell disease is not contagious and that clear communication with families and communities is essential for improving understanding\, genetic counselling and health-seeking behaviour. \nA major focus of the session was the burden of sickle cell disease in sub-Saharan Africa and Kenya. Dr. Awuonda noted that without timely intervention\, many children born with sickle cell disease in high-burden settings die before the age of five. This framed the case for newborn screening as a life-saving public health intervention\, rather than a specialist service alone. \nThe discussion explored screening modalities\, including point-of-care testing and laboratory-based approaches\, and highlighted the importance of linking screening to action. Early detection only improves outcomes when it is followed by caregiver education\, prophylactic care\, vaccination\, access to hydroxyurea where appropriate\, routine monitoring and clear referral pathways. \nDr. Sophie Uyoga shared experience from Kilifi\, where structured sickle cell care has combined clinical service delivery\, research\, patient follow-up and community engagement. The session highlighted how early testing\, routine monitoring\, access to hydroxyurea and caregiver education can improve survival and health-seeking behaviour. \nThe discussion also addressed the realities of long-term care\, including transition from paediatric to adult services\, psychosocial support\, affordability\, access to diagnostics\, transfusion planning and the importance of maintaining patients in care. The speakers emphasised that sickle cell disease should not be viewed as a death sentence. With early diagnosis\, structured follow-up and supportive systems\, patients can live fuller and longer lives. \nThe session reinforced the need to operationalise infant screening policy\, strengthen financing\, improve point-of-care capacity\, support data systems and build care pathways that connect newborn screening to lifelong care. \nKey Takeaways \n\nNewborn screening is critical for early identification and timely intervention in sickle cell disease.\nScreening must be linked to care\, including caregiver education\, prophylaxis\, vaccination\, routine monitoring and referral pathways.\nSickle cell disease is inherited and not contagious; community education remains important for reducing stigma.\nHydroxyurea\, routine monitoring and structured clinical follow-up can reduce complications and improve outcomes.\nTransition from paediatric to adult care requires stronger planning\, psychosocial support and retention strategies.\nPolicy\, financing\, data systems and point-of-care testing are essential for scaling sickle cell care across Kenya. URL:https://kesho-kenya.org/event/sickle-cell-disease-4/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/06/WhatsApp-Image-2026-06-23-at-10.10.49-AM-e1782290824589.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260709T190000 DTEND;TZID=Africa/Nairobi:20260709T203000 DTSTAMP:20260709T131831Z CREATED:20260709T131009Z LAST-MODIFIED:20260709T131831Z UID:41811-1783623600-1783629000@kesho-kenya.org SUMMARY:Management of Endometrial Cancer DESCRIPTION:A Multidisciplinary Approach in the Management of Endometrial Cancer \n📅 9th July 2026\n⏰ 7PM – 8:30PM EAT \nJoin our expert panel:\n👨‍⚕️ Dr. Alfred Mokomba — Surgical Management and Risk Stratification\n👩‍⚕️ Dr. Catherine Nyongesa — Adjuvant Radiotherapy and Multidisciplinary Decision-Making\n🎙️ Moderated by Dr. Edward Sang \nDon’t miss this insightful session bringing together leading oncologists to discuss best practices in endometrial cancer care. \n \n CLICK TO REGISTER URL:https://kesho-kenya.org/event/management-of-endometrial-cancer/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-09-at-4.04.41-PM-e1783603095456.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260716T190000 DTEND;TZID=Africa/Nairobi:20260716T203000 DTSTAMP:20260717T085319Z CREATED:20260716T130048Z LAST-MODIFIED:20260717T085319Z UID:41816-1784228400-1784233800@kesho-kenya.org SUMMARY:Advancing Cardio-Oncology in East Africa DESCRIPTION:Advancing Cardio-Oncology in East Africa \nFrom Evidence to Everyday Practice \nCPD Accredited \n\nDate: Thursday\, 16th July 2026\nTime: 7:00 PM – 8:30 PM EAT\n\nSpeakers \n\nDr. Anne Mwirigi\n\nConsultant Haematologist & Assistant ProfessorAga Khan University Hospital\, Nairobi \n\n\nDr. Kieran Mwazo\n\nConsultant CardiologistHead of the Cardiology Division\,Coast General Teaching and Referral Hospital\, Mombasa \n\nDr. Joseph Abuodha\n\nConsultant Medical OncologistDepartment of Haematology and Oncology\,Aga Khan University Hospital\, Nairobi \n\nModerator \n\nProf. Arjun Ghosh\n\nConsultant CardiologistBarts Heart Centre\,St. Bartholomew’s Hospital\, London & University College London Hospital \nOrganizers \n\nKESHO – Kenya Society of Haematology & Oncology\nKCS – Kenya Cardiac Society\n\n \n CLICK TO REGISTER \n \n  \n  URL:https://kesho-kenya.org/event/advancing-cardio-oncology-in-east-africa/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-16-at-12.28.17-PM-e1784206835252.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260723T193000 DTEND;TZID=Africa/Nairobi:20260723T203000 DTSTAMP:20260721T143134Z CREATED:20260721T125010Z LAST-MODIFIED:20260721T143134Z UID:41828-1784835000-1784838600@kesho-kenya.org SUMMARY:Management of Treatment-Induced Neurotoxicity DESCRIPTION:Management of Treatment-Induced Neurotoxicity session \n23rd July 2026\, 7–8:30 PM EAT\, \nFeaturing Dr. Herman Ekea\, Dr. Karishma Sharma\, and Dr. Juzar Hooker \n \n Click to Register URL:https://kesho-kenya.org/event/management-of-treatment-induced-neurotoxicity/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-20-at-12.54.09-PM-4-e1784644283295.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260730T193000 DTEND;TZID=Africa/Nairobi:20260730T203000 DTSTAMP:20260728T134117Z CREATED:20260728T131820Z LAST-MODIFIED:20260728T134117Z UID:41839-1785439800-1785443400@kesho-kenya.org SUMMARY:Implementing Precision Oncology in LMICs DESCRIPTION:Implementing Precision Oncology in LMICs:\nFrom Diagnosis to Clinical Decision-Making \nDate: 30th July 2026\nTime: 7 PM – 8:30 PM EAT \nSpeaker\nProf. Shahin Sayed\nAssociate Professor & Consultant\, Anatomical Pathology and Cytology\, Department of Pathology\, Medical College\, Aga Khan University; Chair & Laboratory Director. Pathology\, AKUH\, N\nThe Diagnostic Foundations of Precision Oncology: Pathology\, Biomarkers and Molecular Testing \nSpeaker\nProf. Chite Asirwa\nMedical Oncologist & Hematologist; CEO\, International Cancer Institute\nPrecision Oncology in LMICs: Current Landscape\, Clinical Application and the Road Ahead \nModerator\nProf. Nicholas Abinya\nConsultant Medical Oncologist\, Nairobi Hospital Cancer Centre \n \n Click to Register URL:https://kesho-kenya.org/event/implementing-precision-oncology-in-lmics/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-28-at-12.07.44-PM-3-e1785245724838.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20261119T080000 DTEND;TZID=Africa/Nairobi:20261121T170000 DTSTAMP:20260602T074510Z CREATED:20260407T183641Z LAST-MODIFIED:20260602T074510Z UID:41566-1795075200-1795280400@kesho-kenya.org SUMMARY:The 9th Kenya International Cancer Conference DESCRIPTION: URL:https://kesho-kenya.org/event/2026-kenya-international-cancer-conference/ CATEGORIES:Conferences,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/04/WhatsApp-Image-2026-06-02-at-10.31.48-AM-e1780386294605.jpeg END:VEVENT END:VCALENDAR